AIMSTM enables an innovative biomarker led drug pipeline
Focusing on emerging drug targets, Protai's AIMSTM platform paves the way to a unique precision medicine approach, facilitating an accelerated drug development process
PRT-001
KAT6A degrader (Oncology)
Launched: 2025 IND: 2027
PRT-002
Allosteric PPIi (I&I)
PRT-003
Oncology
PRT-004
I&I
STAGE
Discovery
Lead optimization
IND Enabling
Collaborate with us
Our portfolio and pipeline assets extend from early discovery through to late preclinical and we are looking to engage with pharma companies with potential interest in partnering/licensing our assets.
